

Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration

Simris Group AB (publ), through its wholly owned subsidiary Simris Biologics GmbH, has signed a non-binding concept sheet with a EU based biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs). The concept sheet outlines the intention of both parties to explore a potential Research, Development Option and License Agreement focused on Simris' proprietary cytotoxin payloads derived from cyanobacteria.

The aim of the concept sheet is to provide a framework for continued discussions and negotiations toward a definitive agreement.

"This marks an exciting step in Simris Biologics' strategy to expand the potential applications of our toxin payloads by partnering with established innovators in targeted cancer therapeutics," said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB. "The discussions outlined in the concept sheet are focused on evaluating the integration of Simris' cyanobacteria-derived payloads into next-generation ADC constructs."

The concept sheet is non-binding and intended solely as a basis for further discussion. It does not constitute an offer or create any binding legal obligations between the parties. Any future collaboration remains subject to the successful negotiation and execution of a definitive agreement.

Further updates will be provided as material developments occur.

Contact Details:

Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com

About Simris Group AB (PUBL):

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-02 08:55 CEST.

Attachments

[Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration](#)